Aptamer reports decent technical, commercial progress

Aptamer Group reported solid progress on both the technical and commercial fronts on Friday as it held its annual general meeting.

The AIM-traded firm said that since its recapitalisation in August, it had undergone a cost reduction initiative, streamlining production processes to boost capacity, and decreased material requirements from customers.

It also continued to expand and convert its commercial pipeline, with a recent partnership involving a genetic medicines company to advance Optimer development, facilitating targeted delivery of new medicines.

At 1121 GMT, shares in Aptamer Group were down 2.5% at 1.17p.

Reporting by Josh White for Sharecast.com.